受到行贿调查,葛兰素史克销售额锐减 | 德国之声 来自德国 介绍德国 | DW | 23.10.2013
  1. Inhalt
  2. Navigation
  3. Weitere Inhalte
  4. Metanavigation
  5. Suche
  6. Choose from 30 Languages

新闻广角

受到行贿调查,葛兰素史克销售额锐减

An employee walks inside a GlaxoSmithKline (GSK) office in Shanghai July 16, 2013. China must crack down on commercial bribery by multinational firms, the country's top state paper said on Wednesday, two days after police accused British drugmaker GlaxoSmithKline of the widespread bribery of Chinese officials and doctors. Picture taken July 16, 2013. REUTERS/Stringer (CHINA - Tags: BUSINESS HEALTH CRIME LAW) CHINA OUT. NO COMMERCIAL OR EDITORIAL SALES IN CHINA

葛兰素史克上海办公室

美联社、法新社报道,葛兰素史克宣布,第三季度在中国的药物与疫苗销售额下降61%。该公司此前受到向医生和医院行贿指控并受到调查。周三,该公司首席执行官维提(Andrew Witty)表示,在中国的销售额锐减令人失望,但公司受调查带来的长期影响如何,目前判断为时过早。今年7月,葛兰素史克承认在华分公司高级雇员有可能触犯了当地法律。